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Summary
Background The past two decades have seen expansion of childhood vaccination programmes in low-income and 
middle-income countries (LMICs). We quantify the health impact of these programmes by estimating the deaths and 
disability-adjusted life-years (DALYs) averted by vaccination against ten pathogens in 98 LMICs between 2000 and 2030.
Methods 16 independent research groups provided model-based disease burden estimates under a range of vaccination 
coverage scenarios for ten pathogens: hepatitis B virus, Haemophilus influenzae type B, human papillomavirus, 
Japanese encephalitis, measles, Neisseria meningitidis serogroup A, Streptococcus pneumoniae, rotavirus, rubella, and 
yellow fever. Using standardised demographic data and vaccine coverage, the impact of vaccination programmes was 
determined by comparing model estimates from a no-vaccination counterfactual scenario with those from a reported 
and projected vaccination scenario. We present deaths and DALYs averted between 2000 and 2030 by calendar year 
and by annual birth cohort.
Findings We estimate that vaccination of the ten selected pathogens will have averted 69 million (95% credible interval 
52–88) deaths between 2000 and 2030, of which 37 million (30–48) were averted between 2000 and 2019. From 2000 
to 2019, this represents a 45% (36–58) reduction in deaths compared with the counterfactual scenario of no vaccination. 
Most of this impact is concentrated in a reduction in mortality among children younger than 5 years 
(57% reduction [52–66]), most notably from measles. Over the lifetime of birth cohorts born between 2000 and 2030, 
we predict that 120 million (93–150) deaths will be averted by vaccination, of which 58 million (39–76) are due to 
measles vaccination and 38 million (25–52) are due to hepatitis B vaccination. We estimate that increases in vaccine 
coverage and introductions of additional vaccines will result in a 72% (59–81) reduction in lifetime mortality in the 
2019 birth cohort.
Interpretation Increases in vaccine coverage and the introduction of new vaccines into LMICs have had a major 
impact in reducing mortality. These public health gains are predicted to increase in coming decades if progress in 
increasing coverage is sustained.
Funding Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Vaccines have been responsible for substantial reductions 
in mortality1–5 and are among the most cost-effective 
health interventions.6–8 In addition to direct protection 
provided to vaccinated individuals, high levels of 
vaccination coverage offer indirect protection (herd 
immunity) to the remaining unvaccinated individuals in 
a population. The timescale of vaccine impact varies 
considerably; for some childhood diseases (such as 
measles, rotavirus, and pneumococcal disease), impact is 
seen rapidly, whereas for human papillomavirus (HPV) 
and hepatitis B, vaccine impact is commonly seen over 
a much longer timescale in the reduction of adult 
morbidity and mortality.
WHO introduced the Expanded Programme on 
Immunization in 1974.9 This programme, which was 
supported by UNICEF and global donors, succeeded in 
delivering substantial increases in coverage of routine 
childhood vaccines; for example, global coverage of three 
doses of diphtheria-tetanus-pertussis vaccine (DTP3) 
increased from just over 20% in 1980 to more than 75% 
in 1990.10 However, as coverage plateaued in the 1990s, 
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concerns grew around the sustainability of these gains, 
eventually leading to the formation of Gavi, the Vaccine 
Alliance, in 1999.11 Gavi’s mission is to sustain and 
increase coverage and improve access to new vaccines 
in low-income and middle-income countries (LMICs).12 
Since its founding, it has supported the immunisation of 
more than 700 million children in LMICs.13 Global targets 
for vaccination have also continued to grow in ambition; 
the Global Vaccine Action Plan framework was launched 
in 2012 by WHO with the aim of preventing millions 
of deaths by 2020 through access to vaccines in all 
countries. This was further reinforced by target 3.8 of 
the Sustainable Development Goals calling for access to 
vaccines for all by 2030.14
Due to incompleteness and the inconsistent quality of 
death registration and disease surveillance systems 
in many LMICs, directly measuring the impact of 
vaccination programmes on mortality and morbidity is 
not always possible. Therefore, mathematical models are 
a valuable tool for extrapolating from available disease 
burden and pathogen surveillance data to generate 
impact estimates and to generate projections of the 
impact of future vaccine coverage to inform investment 
planning.
To improve the quality and coordination of vaccine 
impact assessment, the Vaccine Impact Modelling 
Consortium (VIMC) was formed in late 2016, with the 
support of Gavi and the Bill & Melinda Gates Foundation. 
VIMC currently comprises 18 modelling groups coor-
dinated by a secretariat at Imperial College London 
(London, UK), and it models vaccination impact against 
diseases caused by ten different pathogens across 
98 countries (about 69% of the world’s population 
in 2018), including the 73 countries currently eligible for 
Gavi support.
This study presents the first complete set of vaccine 
impact estimates generated since VIMC was formed, 
quantifying impact over calendar year and annual birth 
cohorts between 2000 and 2030, in terms of deaths 
and disability-adjusted life-years (DALYs) averted. The 
pathogens included were hepatitis B virus, Haemophilus 
influenzae type B, HPV, Japanese encephalitis, measles, 
Neisseria meningitidis serogroup A, Streptococcus 
pneumoniae (prevented by the pneumococcal conjugate 
vaccine [PCV]), rotavirus, rubella virus, and yellow fever 
virus. VIMC does not currently assess the impacts of 
DTP vaccine,1 cholera vaccine, or polio vaccines. The 
vaccine impact estimates from VIMC are used to support 
the monitoring of existing vaccination programmes and 
inform future investment strategy.
Methods
Models
Modelling groups from different institutions with disease-
specific expertise provided pathogen-specific vaccine 
impact estimates for hepatitis B virus, H influenzae type B, 
HPV, Japanese encephalitis, measles, N meningitidis 
serogroup A, S pneumoniae (prevented by PCV), rotavirus, 
rubella virus, and yellow fever virus (table 1). Two math-
ematical models were used for each pathogen other than 
hepatitis B virus, which had three, and yellow fever, which 
had one. Including multiple models for each pathogen 
facilitates assessment of structural uncertainty in models. 
Each model represents the impact of vaccine coverage and 
efficacy on national-level disease burden (and in some 
cases disease transmission dynamics) to estimate vaccine 
impact. Model descrip tions and the list of 98 LMICs 
included in the analysis are provided in appendix 2 
(pp 14–35, 45–48). Static models estimate only the direct 
effect of vaccination on vaccinated cohorts, assuming that 
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Research in context
Evidence before this study
Immunisation has been a key tool for reducing childhood 
mortality in low-income and middle-income countries (LMICs) 
in the past few decades. However, quantitative assessment of 
the impact of recent expansion of vaccination programmes on 
mortality and morbidity has been scarce. We searched PubMed 
up to Sept 25, 2019, without date limits or language 
restrictions, using the search terms “vaccine* AND impact AND 
estimate* AND (mortality or morbidity)”. We found 15 studies 
that estimated population-level mortality impact of past 
vaccination against at least one of the pathogens considered in 
our study, in at least one LMIC. Of these, three studies 
considered impact in more than one country, one of which 
assessed the impact of multiple vaccines in multiple countries. 
The latter study was published by the predecessor of the 
Vaccine Impact Modelling Consortium and reported the 
previous estimates of the impacts of vaccination on mortality 
in the 73 countries supported by Gavi.
Added value of this study
The current study advances previous work in terms of scale 
(number of countries, number of pathogens, and time period), 
in its emphasis on standardising model inputs (vaccine coverage 
and demography) and outputs (mortality and disability-adjusted 
life-years averted), and in assessing uncertainty in estimates of 
vaccine impact. Standardisation allowed impacts to be combined 
across and compared between vaccines. Uncertainty was 
assessed via probabilistic sensitivity analysis and by combining 
outputs from multiple models for each disease.
Implications of all the available evidence
Rigorous estimates of the impact of childhood vaccination 
programmes on morbidity and mortality inform public health 
investment decisions made by countries and global donors. 
The results highlight the importance of maintaining and 
increasing vaccine coverage to sustain gains made in reducing 
infectious disease-related mortality in LMICs.
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pathogen transmission intensity is not modified by 
vaccination coverage. Dynamic models simulate infectious 
disease transmission dynamics and model both the 
direct effect of vaccination on vaccinated cohorts and the 
indirect effect of vaccination on unvaccinated populations.
Standardised demographic data (live births per year 
and death rates) based on the UN World Population 
Prospects (UNWPP) 2017 was used for all countries.16 
Similarly, standardised national-level estimates of 
vaccination coverage for each vaccine considered were 
provided by the VIMC secretariat to each group. Past 
coverage in all countries for 1980–2016 was obtained 
from WHO–UNICEF Estimates of National Immu-
nization Coverage, as published in July, 2017.17 Future 
coverage estimates from 2017 to 2030 were based on 
Gavi’s operational forecast as of October, 2017, for the 
countries eligible for Gavi support. Gavi’s operational 
forecasts assume likely dates of vaccine introduction 
on the basis of non-binding expressions of interest 
from eligible countries, applications to Gavi for vaccine 
support, intended introductions as reported to WHO, 
and assessment of country capacity to introduce a spe-
cific vaccine in a specific timeframe. After introduction, 
coverage of new vaccines was typically assumed to reach 
coverage of a reference vaccine (eg, coverage of DTP3) 
within 2–3 years, after which coverage was assumed to 
increase by 1% per year up to a maximum of 90% or 
95%, depending on the vaccine.1 For the 25 countries 
considered not supported by Gavi, and for years after 
2030 for countries in Gavi’s portfolio, an annual 1% 
increase in coverage was assumed from 2017 up to a 
maximum of 90% or the historic high coverage achieved 
(if >90%). For newly introduced vaccines with only an 
introduction date and no Gavi coverage forecast, we 
assumed that coverage would increase to the same 
coverage as pentavalent (hepatitis B, H influenzae type B, 
DTP3) vaccine in that country in the first 3 years and 
subsequently increase by 1% per year. Estimates of the 
number of vaccines received per child by year were 
generated from these coverage estimates and projections, 
assuming independence of coverage between vaccines.
Procedures and outcomes
Disease burden was quantified by deaths and DALYs 
stratified by age. DALYs measure the years of healthy life 
lost due to premature death and disability from the disease. 
They are the sum of years of life lost through premature 
mortality and years lived with disability. No discounting or 
weighting was applied in the calculation of DALYs.
Age-stratified pathogen-specific disease burden esti-
mates (deaths and DALYs) for annual birth cohorts 
between 2000 and 2030 were generated by each 
modelling group. Corresponding estimates for the 
counterfactual scenario, assuming no vaccination had 
occurred after 2000, were also produced. Supplemen tary 
immunisation activities, other immunisation campaigns 
(such as yellow fever reactive campaigns to outbreaks), 
and second doses were modelled when relevant. For 
rubella, only disease burden from congenital rubella 
syndrome18 was assessed, because rubella usually causes 
only mild disease in infected individuals.
The impact of vaccination was assessed by comparing 
the counterfactual scenario (no vaccination) with the 
reported and projected vaccination scenarios. Two forms 
of aggregation were used to present the results: by 
calendar year and by year of birth. The estimates by 
calendar year were used to assess the difference in 
burden between the reported and projected vaccination 
and no-vaccination scenarios for a specific year and to 
give a cross-sectional view of impact. The estimates by 
year of birth were used to sum disease burden across 
every year of life for each yearly birth cohort (born 
between 2000 and 2030), and also to assess the difference 
between reported and projected vaccination and no-
vaccination scenarios, and therefore gives a lifetime view 
of vaccine impact. The population-attributable benefit of 
vaccination for each pathogen was estimated as the 
proportion of annual deaths due to each pathogen that 
would be prevented by vaccination.
We used model averaging to derive impact estimates, 
with each model for a pathogen given equal weighting. 
Uncertainty in model estimates was assessed by 
generating 200 sets of estimates from each model, 
probabilistically sampling over model parameter uncer-
tainty. The same randomly sampled sets of parameters 
were used for both vaccination and no-vaccination 
model runs, allowing uncertainty in vaccine impact 
to be assessed. Central pathogen-specific estimates 
presented here represent averages over all such samples 
from every model available for each pathogen. The 
Vaccination schedule Lead institution for model (model type)
Hepatitis B virus Birth dose and three infant doses 
(<1 year)
Center for Disease Analysis (dynamic); Imperial 
College London (dynamic); independent model 
developed by Goldstein and colleagues15 (static)
Human papillomavirus Two doses for adolescent girls 
(9–14 years)




Three infant doses (<1 year) Johns Hopkins University (static); LSHTM (static)
Japanese encephalitis Infant dose (<1 year) Oxford University (dynamic); University of 
Notre Dame (dynamic)
Measles First dose at ≤1 year, second dose 
at <2 years








Three infant doses (<1 year) Johns Hopkins University (static); LSHTM (static)
Rotavirus Two infant doses (<1 year) Johns Hopkins University (static); LSHTM (static)
Rubella First dose at <1 year, second dose 
at <2 years
Johns Hopkins University (dynamic); Public 
Health England (dynamic)
Yellow fever Infant dose (<1 year) Imperial College London (static)
Detailed descriptions of the models are provided in appendix 2 (pp 14–35). LSHTM=London School of Hygiene & 
Tropical Medicine. PCV=pneumococcal conjugate vaccine.
Table 1: Vaccination schedules and model information for the ten considered pathogens
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95% credible intervals (CrIs; 2∙5% and 97∙5% quantiles) 
presented for each pathogen were derived by combining 
the probabilistic distributions of estimated impact from 
all the models available for that pathogen.
Estimates involving aggregation across pathogens 
were generated via a bootstrap approach under the 
simplifying assumption that the drivers of uncertainty 
in each model are independent of those in any other 
model. For each model, a random sample of the statistic 
of interest was drawn from the 200 probabilistic runs. 
These model-specific samples were combined by 
averaging them across models of the same pathogen 
and then sum ming the resulting pathogen-specific 
estimates across pathogens. Means and 2·5% and 
97·5% quantiles of 100 000 such bootstrap samples were 
calculated to derive central estimates and 95% CrIs.
The main text of this Article focuses on presenting 
vaccine impacts on mortality; more detailed estimates 
of mortality impacts and estimates of DALYs averted by 
vaccination are provided in appendix 2 (pp 49–58).
Role of the funding source
This report was compiled by all coauthors, including one 
coauthor from Gavi. Other funders had no role in study 
design, data collection, data analysis, data interpretation, 
or writing of the report. All authors had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
In this study of the health impact of vaccination against 
ten pathogens, the average number of vaccines received 
per child increased across the majority of the 98 LMICs 
(appendix 2 pp 45–48) between 2000 and 2019 
(figure 1A–C). Both increases in the coverage of existing 
vaccines (eg, measles-containing vaccines) and the 
introduction of new vaccines (eg, rota virus vaccine) 
contribute to this overall trend (figure 1D). Routine 
vaccination against Japanese encephalitis and rotavirus 
began to be introduced from 2006, S pneumoniae (PCV) 
in 2010, HPV in 2014, and N meningitidis sero group A 
in 2016. In addition, coverage increases also reflect the 
increase in countries eligible for Gavi support (appendix 2 
p 48). The increase in vaccination is also reflected in the 
proportion of unvaccinated children (appendix 2 p 9) 
for the 2019 cohort. For different assumptions of the 
correlation of vaccine doses within and between different 
vaccines, the proportion of unvaccinated children in most 
of the countries was less than 0∙1 (appendix 2 pp 5–9).
To assess the impact of vaccination on mortality, 
we quantified the expected burden of disease in the 
counterfactual scenario of no vaccination and estimated 
the impact of observed and projected vaccination 
coverage on that baseline (figure 2). Depending on 
the pathogen considered, long-term trends in disease 
prevalence interact with global population growth and 
ageing, resulting in a variety of projected trends in 
Figure 1: Vaccine coverage across the ten pathogens considered
Vaccine coverage, calculated as the mean number of vaccines received per child born in a specific year, is shown 
for 2000 (A), 2010 (B), and 2019 (C). The colour scale shows the expected number of vaccines received per child in 
each country. (D) Routine vaccine coverage for each pathogen, from 2000 to 2019, averaged across all 
98 countries, except for Japanese encephalitis, Neisseria meningitidis serogroup A, and yellow fever, which were 
averaged across the 16, 26, and 32 endemic countries for those pathogens, respectively. The average was obtained 
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disease-specific mortality in the counterfactual, no-
vaccination scenario. However, for all except two patho-
gens (hepatitis B virus and HPV), vaccination between 
2000 and 2030 was estimated to cause substantial 
reductions in mortality in the same time period. For 
hepatitis B virus and HPV, most mortality was due to 
infections that have already occurred, due to the typically 
long time delay between infection and severe outcomes 
for those infections. Although hepatitis B vaccination 
coverage is now relatively high and projected to increase 
further, most of the impact of this coverage will be seen 
only after 2030. For HPV, most countries have yet to 
introduce vaccination.
The age distribution of mortality varied considerably 
across the ten pathogens because of differences in 
their epidemiology. Mortality attributable to hepatitis B 
and HPV primarily affects those older than 40 years; 
yellow fever, N meningitidis serogroup A, and Japanese 
encephalitis are epidemic diseases that mostly affect 
those younger than 30 years (due to natural immunity 
acquired with age in older adults); mortality for all other 
pathogens was almost entirely focused in children 
younger than 5 years. Most of the mortality reduction 
from measles is attributable to the measles-containing 
vaccine, the first dose of which is not subject to Gavi 
funding.
The estimated numbers of deaths averted by vaccina-
tion in the 98 countries are presented in figure 3 and 
appendix 3 (p 1). Estimates of DALYs averted are presented 
in appendix 2 (p 65). Estimated numbers of deaths and 
DALYs averted among children younger than 5 years are 
also presented in appendix 2 (p 66).
In terms of deaths averted by calendar year (figure 3A), 
69 million (95% CrI 52–88) deaths were estimated to 
be averted between 2000 and 2030, of which 37 million 
(30–48) were averted between 2000 and 2019 (table 2). In 
the 73 Gavi countries, the corresponding values were 
66 million (49–83) deaths averted between 2000 and 2030, 
35 million (28–45) of which were averted between 2000 
and 2019 (appendix 2 p 53). Of the ten pathogens, vac-
cina tion against measles has the largest impact, with 
56 million (39–74) deaths averted between 2000 and 2030 
(54 million [37–70] in the 73 Gavi countries).
Considering deaths averted by birth cohort (figure 3B, 
appendix 2 p 50), the longer-term impact of increasing 
coverage of hepatitis B vaccination becomes clearer. 
Because the majority of hepatitis B deaths (due to liver 
disease) occur in those older than 45 years, the impact 
of vaccination will not be seen in the 2000–30 time 
period (figure 3A) but will start to be seen from 2040 
onwards. Similar arguments apply to HPV vaccination 
(although coverage is substantially lower than for 
Figure 2: Estimates of disease-specific deaths by calendar year, from 2000 to 2030, across 98 countries, for reported and projected vaccine coverage and 
counterfactual (no vaccination) coverage
Lines show estimates of deaths for the two scenarios, for all ages. The corresponding shaded areas show the 95% credible intervals (2·5% and 97·5% quantiles). 
The grey shaded parts show the area where the 95% credible intervals for the two scenarios overlap. PCV=pneumococcal conjugate vaccine.
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hepatitis B); cervical cancer deaths largely occur in 
women older than 50 years, leading to a delay of nearly 
40 years between vaccination and its direct impact on 
mortality. Thus, summing vaccination impact over the 
full lifetimes of the 2000–30 birth cohorts gives a total of 
120 million (95% CrI 93–150) estimated deaths averted, 
of which 65 million (48–83) are in children younger 
than 5 years. In the 73 Gavi countries, the corresponding 
values are 100 million (78–130) deaths averted in the 
2000–30 birth cohorts, of which 62 mil lion (46–78) of 
which are in children younger than 5 years (appendix 2 
p 55). In estimates of deaths averted by pathogen in 
the 2000–30 birth cohorts, more than 53% (45–66) of 
deaths averted are in children under 5 years (appendix 2 
p 50).
The extent to which vaccination reduces overall 
mortality due to the ten pathogens varies substantially 
by country (figure 3C), largely due to historical variations 
in vaccination coverage, but also due to variation in 
the epidemiology of some pathogens by country. We 
estimate vaccination will prevent 72% (95% CrI 59–81) 
of the mortality associated with these ten pathogens 
in the 2019 annual birth cohort across the countries 
considered. This proportion rises to 76% (54–84) if only 
mortality of children younger than 5 years is considered. 
In the 73 Gavi countries, the corresponding values are 
a 72% (57–79) reduction in all-age mortality and a 
76% (54–84) reduction in mortality among children 
younger than 5 years.
In the period 2000–19, we estimate that vaccination in 
the 98 countries reduced overall mortality due to these 
pathogens by 45% (95% CrI 36–58) and mortality among 
children younger than 5 years by 57% (52–66). In the 
73 Gavi countries, these reductions were 48% (39–59) 
and 57% (53–66), respectively. For the period 2020–30, 
we project these reductions will increase to 60% (33–74) 
for overall mortality and 77% (44–86) for mortality among 
children younger than 5 years in all 98 countries 
(64% [35–76] and 78% [44–86], respectively, in the 73 Gavi 
countries).
It is informative to place these estimates in their 
demographic context. Taking the 2019 birth cohort as an 
example, and using UNWPP demographic estimates, we 
estimate that mortality among children younger than 
5 years in the 98 countries would be 45% (95% CrI 31–57) 
higher in the absence of any vaccination against the ten 
pathogens. The total number of deaths (occurring at any 
age) averted in the 2019 birth cohort represent 4∙1% 
(3∙2–5∙0) of the live births in that cohort.
Total impact reflects vaccination coverage as well as 
underlying disease burden and vaccine effectiveness. We 
therefore examine the relative impact of each vaccine, by 
quantifying deaths averted per vaccinated individual for 
each pathogen (table 2, appendix 2 p 50, appendix 3 p 2). 
Although vaccines against measles, H influenzae type B, 
and S pneumoniae have the largest relative impact on 
mortality of children younger than 5 years, vaccines 
against HPV, hepatitis B virus, and yellow fever have the 
largest impact per person vaccinated by year of birth. 
Vaccines against measles and yellow fever have the 
largest impact per person vaccinated by calendar year. 
Yellow fever and HPV vaccination have the largest 
relative impact of all the vaccines considered, with central 
estimates for both of over 16 (95% CrI 5–32) deaths 
averted per 1000 persons vaccinated for the 2000–19 birth 
cohorts.
Because most of the pathogens considered (H influenzae 
type B, Japanese encephalitis, measles, S pneumoniae, 
rotavirus, and rubella) result in mortality of children 
younger than 5 years, the impact of vaccination on DALYs 
largely mirrors the impact on mortality (appendix 2 p 66). 
Because deaths related to hepatitis B and HPV are 
focused in individuals older than 50 years, mortality 
contributes fewer years of life lost for these pathogens, 
but morbidity contributes higher years lived with 
disability for both infections (particularly hepatitis B). 
Estimates of vaccine impact in DALYs averted are 
presented in appendix 2 (pp 49–58).
Figure 3: Estimates of deaths averted by vaccination in 98 countries
(A) Estimates of death averted by calendar year (summing across all ages) and pathogen. (B) Estimates of deaths 
averted by year of birth (summing across lifetime) and pathogen. (C) Proportion of lifetime deaths due to the ten 
pathogens considered in the no-vaccination counterfactual scenario that are predicted to be averted by 
vaccination, by country, across 2000–19 birth cohorts. PCV=pneumococcal conjugate vaccine.
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Discussion
In this study, the health impact of immunisation in 
LMICs is estimated on the largest scale to date, covering 
vaccination programmes against ten pathogens and 
evaluating impact in 98 countries. It represents an 
advance on previous work1 in terms of scale (the number 
Deaths averted, 1000s Deaths averted per 
1000 vaccinated individuals
Deaths averted in children 
<5 years, 1000s
Deaths averted per 
1000 vaccinated children 
<5 years
Hepatitis B virus
2000–19 640 (190–1500) 0·4 (0·1–0·9) 270 (51–1100) 0·2 (0–0·6)
2020–30 1600 (460–2900) 1·0 (0·3–1·8) 230 (59–810) 0·1 (0–0·5)
2000–30 2200 (660–3700) 0·7 (0·2–1·1) 500 (110–1900) 0·1 (0–0·5)
Haemophilus influenzae type B
2000–19 1600 (720–2400) 2·5 (1·1–3·7) 1600 (720–2400) 2·5 (1·1–3·7)
2020–30 2000 (730–3200) 2·4 (0·9–3·7) 2000 (730–3200) 2·4 (0·9–3·7)
2000–30 3600 (1400–5500) 2·4 (1·0–3·7) 3600 (1400–5500) 2·4 (1·0–3·7)
Human papillomavirus
2000–19 0·013 (0–0·031) 0 0 0
2020–30 7·4 (1·4–15·0) 0 0 0
2000–30 7·4 (1·4–15·0) 0 0 0
Japanese encephalitis
2000–19 75 (6·1–190) 0·2 (0–0·4) 52 (4·2–130) 0·2 (0–0·4)
2020–30 160 (16–420) 0·4 (0–0·9) 86 (8·1–230) 0·2 (0–0·5)
2000–30 240 (22–600) 0·3 (0–0·6) 140 (12–350) 0·2 (0–0·5)
Measles
2000–19 33 000 (26 000–44 000) 6·9 (5·5–9·2) 32 000 (26 000–43 000) 7·9 (6·4–11)
2020–30 23 000 (9400–31 000) 9·1 (3·7–12·0) 23 000 (10 000–31 000) 9 (4–12)
2000–30 56 000 (39 000–74 000) 7·7 (5·4–11·0) 55 000 (40 000–73 000) 8·3 (6–11)
Neisseria meningitidis serogroup A
2000–19 73 (12–160) 0·3 (0–0·6) 19 (2–38) 0·1 (0–0·3)
2020–30 140 (52–270) 0·5 (0·2–1·1) 33 (11–59) 0·1 (0–0·2)
2000–30 210 (130–360) 0·4 (0·3–0·7) 52 (32–81) 0·1 (0·1–0·2)
Streptococcus pneumoniae (PCV)
2000–19 610 (320–1100) 2·5 (1·3–4·2) 610 (320–1100) 2·5 (1·3–4·2)
2020–30 1600 (730–2900) 2·3 (1·0–4·1) 1600 (730–2900) 2·3 (1·0–4·1)
2000–30 2200 (1000–4000) 2·3 (1·1–4·1) 2200 (1000–4000) 2·3 (1·1–4·1)
Rotavirus
2000–19 150 (100–200) 0·8 (0·6–1·1) 150 (100–200) 0·8 (0·6–1·1)
2020–30 590 (370–820) 0·8 (0·5–1·1) 590 (370–820) 0·8 (0·5–1·1)
2000–30 740 (470–1100) 0·8 (0·5–1·1) 740 (470–1100) 0·8 (0·5–1·1)
Rubella
2000–19 80 (38–200) 0·1 (0–0·1) 80 (38–200) 0·1 (0–0·2)
2020–30 260 (130–590) 0·1 (0·1–0·3) 260 (130–590) 0·1 (0·1–0·3)
2000–30 340 (180–780) 0·1 (0–0·2) 340 (180–780) 0·1 (0·1–0·2)
Yellow fever
2000–19 1300 (450–2800) 3·5 (1·1–7·1) 500 (150–1100) 2·3 (0·7–4·9)
2020–30 2300 (740–4800) 9·0 (2·8–19·0) 510 (150–1100) 2 (0·6–4·2)
2000–30 3600 (1100–7500) 5·7 (1·8–12·0) 1000 (310–2200) 2·1 (0·7–4·5)
Total
2000–19 37 000 (30 000–48 000) 3·7 (3·0–4·7) 36 000 (29 000–46 000) 4·1 (3·2–5·2)
2020–30 32 000 (17 000–41 000) 3·2 (1·8–4·0) 28 000 (15 000–36 000) 2·9 (1·6–3·7)
2000–30 69 000 (52 000–88 000) 3·4 (2·6–4·3) 64 000 (48 000–82 000) 3·5 (2·7–4·4)
Values are mean estimates (95% credible intervals). Corresponding estimates for disability-adjusted life-years averted are presented in appendix 2 (p 49). PCV=pneumococcal 
conjugate vaccine.
Table 2: Estimated total deaths averted by vaccination and deaths averted per thousand individuals vaccinated in 98 countries, by time period and pathogen
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of pathogens and countries considered) and in the 
emphasis of VIMC on standardising model inputs 
(vaccine coverage and demography) and outputs (age-
specific mortality and DALYs by year of birth cohort and 
age). Such standardisation allows impacts to be combined 
across, and compared between, vaccines.
Our analysis highlights where the greatest gains from 
future investments in improving vaccine coverage are to 
be made. We predict increasing HPV coverage in girls 
will avert more deaths per person vaccinated than any 
other immunisation activity, whereas increasing PCV 
coverage will give the largest reductions in mortality 
among children younger than 5 years.
We find that immunisation programmes in the 
98 countries considered will result in individuals born 
in 2019 experiencing 72% lower mortality due to those 
ten pathogens over their lifetime than they would 
with no immunisation. Furthermore, in the absence of 
vaccination, we estimate that all-cause mortality among 
children younger 5 years would be 45% higher than 
currently observed. These impacts are a testament to 
both the public health benefit of vaccines overall and the 
sustained investment in increasing global vaccination 
coverage in the past two decades. They also highlight 
what might be lost if current vaccination programmes 
are not sustained, and thus provide quantitative evidence 
supporting both donor and country investments in 
vaccination programmes.
When compared with mortality estimates for measles 
from the Global Burden of Disease (GBD) Study 2017, we 
find some differences between 2000 and 2010. These are 
likely to be driven by differences in source data and model 
types. For example, the GBD measles estimates are based 
on static models, whereas the two VIMC models are both 
dynamic. Further comparison is provided in appendix 2 
(pp 10–12).
Deriving these impact estimates is far from straight-
forward. Cause-specific mortality data in the LMICs 
considered is not widely available, making direct obser-
vational assessment of impact challenging. However, to 
inform monitoring and decision-making, countries and 
inter national organisations such as Gavi require projec-
tions of potential impact under a range of investment 
scenarios. To fill these gaps, mathematical and statistical 
models can be used to extrapolate data on levels of 
current infection (eg, case detection from active surveil-
lance), past infection (eg, serosurveys), or both, to sites 
and countries without such data. These models can also 
be used to project future trends given information about 
vaccine coverage.
In addition, our study has focused on quantifying 
uncertainty in vaccine impact. Given the scarce explicit 
data on pathogen-specific disease burden available in 
many of the 98 countries considered, nearly all models 
need to extrapolate from settings where data are available 
to those where data are absent. This, together with 
imperfect knowledge of aspects of the epidemiology of 
each pathogen (eg, case-fatality ratios, transmissibility, 
disease progression rates) means that uncertainty in 
vaccine impact estimates from a single model can be 
substantial. Here, this uncertainty is quantified probabi-
listically, with each modelling group providing 200 model 
runs spanning the range of parametric uncertainty in 
their models.
A second source of uncertainty is structural; different 
modelling groups make different subjective choices 
about how to represent disease epidemiology and might 
use different data for model parameterisation. In 
addition, the models within VIMC vary substantially in 
their type (static cohort models vs transmission-dynamic 
models), in their complexity (eg, in the representation of 
age effects), and in their approaches to calibration and 
validation (from formal statistical likelihood approaches 
to more ad-hoc calibration). VIMC therefore includes at 
least two models for each pathogen (with the exception of 
yellow fever) and combines results from different models 
to derive central estimates of impact and to better 
quantify underlying uncertainty.
A limitation of our current analysis is that we do not 
currently evaluate uncertainty in demographic estimates 
and estimates of past and future vaccine coverage. 
Developing principled approaches to doing so is a topic 
of current research, but is made challenging by the 
paucity of information available on uncertainty in 
UNWPP demographic estimates and in WHO–UNICEF 
Estimates of National Immuniza tion Coverage and Gavi 
operational forecast vaccine coverage estimates.
In addition, our study has only focused on 98 LMICs. 
The countries considered here have the highest burden 
from the ten pathogens considered (appendix 3 p 5). 
Therefore, there has been a greater focus on supporting 
vaccine intro duction and implementation in these 
countries, mainly through Gavi (appendix 3 p 4). These 
98 countries include the 73 countries eligible for Gavi 
support1 and 25 other countries that are of interest to the 
funders.
For most vaccines not yet introduced in some countries, 
we assume that once the vaccine were to be introduced in 
that country, the coverage would reach the same coverage 
of a reference vaccine (eg, DTP3) in 2–3 years. However, 
in some countries, there have been substantial delays in 
implementing the vaccine due to shortages in supply,19 
and some countries, such as India, have initially 
introduced the vaccine in a few states to assess the 
feasibility of a new oral vaccine into their programme.20 
Therefore, the use of a reference vaccine for rotavirus 
vaccination coverage for countries that have had 
problems or delays in introduction and scale-up might 
have led to an overestimation of impact.
The majority of models within VIMC adopt a bottom-
up approach to modelling disease burden and thus the 
impact of vaccination. These models represent time-
varying and age-varying pathogen-specific infection or 
disease rates in each country, and model mortality as 
For GBD 2017 data see 
http://ghdx.healthdata.org
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affecting a fraction of those infected by applying a case-
fatality ratio (generally estimated from a combination of 
longitudinal epidemiological studies and surveillance 
data) to resulting case incidence estimates. Because the 
disease burden attributed to each pathogen is modelled 
separately, there is a theoretical risk of overestimating 
deaths due to a failure to account for competing causes of 
mortality, particularly in children younger than 5 years, 
in whom mortality is concentrated. However, in the 2019 
annual birth cohort, UNWPP projections estimate all-
cause mortality among children younger than 5 years to 
be 4∙9% for the 98 countries considered. We estimate the 
ten pathogens considered in this study will cause 
approximately a seventh of this (0∙7% [95% CI 0∙5–1∙4%] 
of all-cause mortality). With such low absolute propor-
tions, the effect of competing hazards of death on overall 
mortality estimates is negligible. Conversely, when 
assessing deaths averted, we consider the counterfactual 
scenario of no vaccination for each vaccine antigen 
separately, subsequently summing across all vaccines, 
because one child’s life can be saved multiple times.
For most pathogens, we currently model infection risk as 
homogeneous within individual countries (with the 
exceptions of the yellow fever, N meningitidis serogroup A, 
and Japanese encephalitis models). Furthermore, no 
models in this study account for geographic or socio-
economic clustering of vaccine coverage, or for any 
potential correlation between access to health care 
(including vaccines) and disease risk. Thus, we may not be 
accounting for disadvantaged subpopulations in countries 
with lower than average access to vaccines, higher than 
average intrinsic exposure to infection, or both. Subnational 
stratification of vaccine impact estimates is a priority for 
future work but require similarly fine-grained estimates of 
vaccine coverage21 and disease burden.
Last, in making long-term projections of disease 
burden and intervention impact, it is necessary to make 
assumptions about the likely improvements in treat-
ment and disease outcomes in future decades. This is 
particularly relevant for hepatitis B and HPV, for which 
cancer screening and treatment services can make a 
substantial difference to disease-related mortality,22 and 
for measles, for which decreasing background mortality 
among children younger than 5 years can significantly 
reduce case-fatality ratios.23 The HPV and hepatitis B 
models included in VIMC currently make conservative 
(ie, relatively pessimistic) assumptions about improve-
ments in cancer screening and treatment in low-income 
countries.
More generally, the estimates provided here should 
not be viewed as immutable; our understanding of 
the epidemiology and disease burden caused by all 
ten pathogens continues to improve, and models of those 
diseases should likewise continue to be refined. In 
addition, future vaccine coverage is unlikely to precisely 
match the coverage projections used here. Thus, the 
estimates of the impact of past immunisation activities 
and projections of future impact will also change. 
However, the results in this paper provide the most 
comprehensive and definitive assessment to date of the 
impact of the dramatic advances in immunisation 
coverage in LMICs in the last two decades.
Finally, it is crucial to increase vaccine coverage and 
maintain high coverage levels in all countries to avoid the 
coverage gains achieved since 2000 being undone. This 
effort requires continued political commitment, funding, 
civil society engagement (in promoting vaccine benefits 
and countering vaccine hesitancy), improving public 
trust and confidence in the safety and efficacy of vac-
cines,24 and strengthening immunisation programmes 
through education, training, and supervision.25
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